These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12661577)

  • 21. A prospective, randomized, double-blind study of the tolerability of rifapentine 600, 900, and 1,200 mg plus isoniazid in the continuation phase of tuberculosis treatment.
    Bock NN; Sterling TR; Hamilton CD; Pachucki C; Wang YC; Conwell DS; Mosher A; Samuels M; Vernon A;
    Am J Respir Crit Care Med; 2002 Jun; 165(11):1526-30. PubMed ID: 12045127
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Drugs for tuberculosis.
    Med Lett Drugs Ther; 1988 Apr; 30(763):43-4. PubMed ID: 3352531
    [No Abstract]   [Full Text] [Related]  

  • 23. [The rational basis for the treatment of tuberculosis].
    Favez G
    Schweiz Med Wochenschr; 1971 Feb; 101(6):203-7. PubMed ID: 5563154
    [No Abstract]   [Full Text] [Related]  

  • 24. Rifampicin/pyrazinamide therapy should not be used for latent tuberculosis infection.
    Garca-Doval I
    J Am Acad Dermatol; 2004 May; 50(5):801; author reply 801-2. PubMed ID: 15097974
    [No Abstract]   [Full Text] [Related]  

  • 25. Short-course therapy with rifampin plus isoniazid, compared with standard therapy with isoniazid, for latent tuberculosis infection: a meta-analysis.
    Ena J; Valls V
    Clin Infect Dis; 2005 Mar; 40(5):670-6. PubMed ID: 15714411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection.
    Yu WC; Lai ST; Chiu MC; Chau TN; Ng TK; Tam CM
    Int J Tuberc Lung Dis; 2006 Jul; 10(7):824-5. PubMed ID: 16850548
    [No Abstract]   [Full Text] [Related]  

  • 27. Tuberculosis in the elderly: treating the "white plague".
    Iseman MD
    Geriatrics; 1980 Mar; 35(3):90-107. PubMed ID: 7353794
    [No Abstract]   [Full Text] [Related]  

  • 28. Treatment of lymph node tuberculosis--a randomized clinical trial of two 6-month regimens.
    Jawahar MS; Rajaram K; Sivasubramanian S; Paramasivan CN; Chandrasekar K; Kamaludeen MN; Thirithuvathas AJ; Ananthalakshmi V; Prabhakar R
    Trop Med Int Health; 2005 Nov; 10(11):1090-8. PubMed ID: 16262733
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 3-month daily rifampicin and isoniazid compared to 6- or 9-month isoniazid for treating latent tuberculosis infection in children and adolescents less than 15 years of age: an updated systematic review.
    Assefa Y; Assefa Y; Woldeyohannes S; Hamada Y; Getahun H
    Eur Respir J; 2018 Jul; 52(1):. PubMed ID: 29748305
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preventing drug-resistant tuberculosis with a fixed dose combination of isoniazid and rifampin.
    Moulding TS; Le HQ; Rikleen D; Davidson P
    Int J Tuberc Lung Dis; 2004 Jun; 8(6):743-8. PubMed ID: 15182145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The effects of antituberculosis drugs on the pharmacokinetics of digitoxin (author's transl)].
    Peters U; Hausamen TU; Grosse-Brockhoff F
    Dtsch Med Wochenschr; 1974 Nov; 99(47):2381-6. PubMed ID: 4426257
    [No Abstract]   [Full Text] [Related]  

  • 32. Three months of once-weekly isoniazid plus rifapentine (3HP) in treating latent tuberculosis infection is feasible in patients with rheumatoid arthritis.
    Chen YM; Liao TL; Chen HH; Chen DY
    Ann Rheum Dis; 2018 Nov; 77(11):1688-1689. PubMed ID: 29674320
    [No Abstract]   [Full Text] [Related]  

  • 33. [Treatment of tuberculous infection: Where we are?].
    Ruiz-Manzano J; Altet Gómez N
    Med Clin (Barc); 2010 Sep; 135(7):310-1. PubMed ID: 20561649
    [No Abstract]   [Full Text] [Related]  

  • 34. Latent tuberculosis infection in children: a call for revised treatment guidelines.
    Finnell SM; Christenson JC; Downs SM
    Pediatrics; 2009 Mar; 123(3):816-22. PubMed ID: 19255008
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunologic reactivity and healing reactions in animals with experimental tuberculosis as affected by chemotherapy].
    Sibirnaia RI; Podusovskiĭ VF; Manastyrskaia OS
    Probl Tuberk; 1985; (5):56-9. PubMed ID: 4048112
    [No Abstract]   [Full Text] [Related]  

  • 36. [Short-term chemotherapy for juvenile tuberculosis].
    Tamura N
    Kekkaku; 1983 Dec; 58(12):625-30. PubMed ID: 6672419
    [No Abstract]   [Full Text] [Related]  

  • 37. Forgotten but not gone.
    Itskowitz MS
    N Engl J Med; 2004 Sep; 351(13):1361; author reply 1361. PubMed ID: 15385671
    [No Abstract]   [Full Text] [Related]  

  • 38. Gynaecomastia during antituberculosis chemotherapy with isoniazid.
    Dixit R; Sharma S; Nawal CL
    J Assoc Physicians India; 2008 May; 56():390-1. PubMed ID: 18700651
    [No Abstract]   [Full Text] [Related]  

  • 39. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

  • 40. An interlaboratory quality control programme for the measurement of tuberculosis drugs.
    Aarnoutse RE; Sturkenboom MG; Robijns K; Harteveld AR; Greijdanus B; Uges DR; Touw DJ; Alffenaar JW
    Eur Respir J; 2015 Jul; 46(1):268-71. PubMed ID: 25882800
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.